Basic fibroblast growth factor (bFGF) modulates gingival growth, and its release from heparan sulfate (HS) in the extracellular matrix (ECM) governs local tissue bioavailability. We identified a heparin/HS interacting protein (HIP/L29) that recognizes specific HS sequences. We hypothesize that HIP/L29, by modulating the interactions of bFGF with HS chains on proteoglycans, could regulate bFGF bioavailability. To investigate interactions between bFGF and HIP/L29, we isolated and cultured fibroblasts from normal gingiva and overgrown gingiva from patients on cyclosporine (CSA). bFGF significantly stimulated gingival fibroblast proliferation with or without heparin. Recombinant human HIP/L29 dramatically decreased bFGF-induced proliferation, but did not alter responses to insulin-like growth factor-1 (IGF-1). Analysis of mitogen-activated protein kinase (MAPK) phosphorylation patterns showed that bFGF stimulation of p44 (Erk-1), but not p42 (Erk-2), also was inhibited by HIP/L29 in a dose-dependent manner. Together, these results support our hypothesis that HIP/L29 modulates the bioavailability and action of bFGF.
Get full access to this article
View all access options for this article.
References
1.
Barber MT, Savage NW, Seymour GJ -1992-. The effect of cyclosporin and lipopolysaccharide on fibroblasts: implications for cyclosporin-induced gingival overgrowth. J Periodontol63:397–404.
2.
Bartold PM -1989-. Regulation of human gingival fibroblast growth and synthetic activity by cyclosporine-A in vitro. J Periodontal Res24:314–321.
3.
Brunius G, Modéer T -1989-. Effect of phenytoin on extracellular 45Ca2+ accumulation in gingival fibroblasts in vitro. J Oral Pathol Med18:485–489.
4.
Chang CD, Meienhofer J -1978-. Solid-phase peptide synthesis using mild base cleavage of N alpha-fluorenylmethyloxycarbonylamino acids, exemplified by a synthesis of dihydrosomatostatin. Int J Pept Protein Res11:246–249.
5.
Chang Z, Meyer K, Rapraeger AC, Friedl A -2000-. Differential ability of heparan sulfate proteoglycans to assemble the fibroblast growth factor receptor complex in situ. FASEB J14:137–144.
6.
Dill RE, Miller EK, Weil T, Lesley S, Farmer GR, Iacopino AM -1993-. Phenytoin increases gene expression for platelet-derived growth factor B chain in macrophages and monocytes. J Periodontol64:169–173.
7.
Friskopp J, Engström P-E, Sundqvist K-G -1986-. Characterization of mononuclear cells in cyclosporine A induced gingival enlargement. Scand J Dent Res94:443–447.
8.
Hassell TM, Romberg E, Sobhani S, Lesko L, Douglas R -1988-. Lymphocyte-mediated effects of cyclosporine on human fibroblasts. Transplant Proc20:993–1002.
9.
Hill SJ, Ebersole JL -1996-. The effect of lipopolysaccharide on growth factor-induced mitogenesis on human gingival fibroblasts. J Periodontol67:1274–1280.
10.
Hoke DE, LaBrenz SR, Höök M, Carson DD -2000-. Multiple domains contribute to heparin/heparan sulfate binding by human HIP/L29. Biochemistry39:15686–15694.
11.
Kataoka M, Shimizu Y, Kunikiyo K, Asahara Y, Yamashita K, Ninomiya M, et al. -2000-. Cyclosporine A decreases the degradation of type I collagen in rat gingival overgrowth. J Cell Physiol182:351–358.
12.
Komaki M, Kang M, Narayanan AS -2000-. Role of MAP kinases p42erk-2/p44erk-1 in cementum-derived attachment-protein-mediated cell attachment. J Dent Res79:1789–1793.
13.
Lavoie JN, L’Allemain G, Brunet A, Müller R, Pouysségur J -1996-. Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway. J Biol Chem271:20608–20616.
14.
Liu S, Hoke D, Julian J, Carson DD -1997a-. Heparin/heparan sulfate -HP/HS- interacting protein -HIP- supports cell attachment and selective, high affinity binding of HP/HS. J Biol Chem272:25856–25862.
15.
Liu S, Zhou F, Höök M, Carson DD -1997b-. A heparin-binding synthetic peptide of heparin/heparan sulfate-interacting protein modulates blood coagulation activities. Proc Natl Acad Sci USA94:1739–1744.
16.
Liu S, Julian J, Carson DD -1998-. A peptide sequence of heparin/heparan sulfate -HP/HS--interacting protein supports selective, high affinity binding of HP/HS and cell attachment. J Biol Chem273:9718–9762.
17.
Marchetti D, Liu S, Spohn WC, Carson DD -1997-. Heparanase and synthetic peptide of heparan sulfate-interacting protein recognize common site on cell surface and extracellular matrix heparan sulfate. J Biol Chem272:15891–15897.
18.
Mariotti A, Hassell T, Jacobs D, Manning CJ, Hefti AF -1998-. Cyclosporin A and hydroxycyclosporine -M-17- affect the secretory phenotype of human gingival fibroblasts. J Oral Pathol Med27:260–266.
19.
McKeehan WL, Wu X, Kan M -1999-. Requirement for anticoagulant heparan sulfate in the fibroblast growth factor receptor complex. J Biol Chem274:21511–21514.
20.
Modéer T, Mendez C, Dahllöf G, Anduren I, Andersson G -1990-. Effect of phenytoin medication on the metabolism of epidermal growth factor receptor in cultured gingival fibroblasts. J Periodontal Res25:120–127.
21.
Murata M, Hara K, Saku T -1997-. Dynamic distribution of basic fibroblast growth factor during epulis formation: an immunohistochemical study in and enhanced healing process of the gingiva. J Oral Pathol Med26:224–232.
22.
Newell J, Irwin CR -1997-. Comparative effects of cyclosporin in glycosaminoglycan synthesis by gingival fibroblasts. J Periodont68:443–447.
23.
Ornitz DM -2000-. FGFs, heparan sulfate and FGFRs: complex interactions essential for development. BioEssay22:108–112.
24.
Raboudi N, Julian J, Rohde LH, Carson DD -1992-. Identification of cell-surface heparin/heparan sulfate-binding proteins of a human uterine epithelial cell line -RL95-. J Biol Chem267:11930–11939.
25.
Rohde LH, Julian J, Babaknia A, Carson DD -1996-. Cell surface expression of HIP, a novel heparin/heparan sulfate binding protein of human epithelial cells and cell lines. J Biol Chem271:11824–11830.
26.
Rostock MH, Fry HR, Turner JE -1987-. Severe gingival overgrowth associated with cyclosporine therapy. J Periodontol57:294–299.
27.
Saito K, Mori S, Iwakura M, Sakamoto S -1996-. Immunohistochemical localization of transforming growth factor β, basic fibroblast growth factor and heparan sulfate glycosaminoglycan in gingival hyperplasia induced by nifedipine and phenytoin. J Periodontal Res31:545–555.
28.
Seymour RA, Thomason JM, Ellis JS -1996-. The pathogenesis of drug-induced gingival overgrowth. J Clin Periodontol23:165–175.
29.
Sugano N, Ito K, Murai S -1998-. Cyclosporine A inhibits collagenase gene expression via AP-1 and JNK suppression in human gingival fibroblast. J Periodontal Res33:448–452.
30.
Tipler LS, Embery G -1985-. Glycosaminoglycan-depolymerizing enzymes produced by anaerobic bacteria isolated from the human mouth. Arch Oral Biol30:391–396.
31.
Whitelock JM, Murdoch AD, Iozzo RV, Underwood PA -1996-. The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases. J Biol Chem271:10079–10086.
32.
Wilson O, Jacobs AL, Stewart S, Carson DD -1990-. Expression of externally-disposed heparin/heparan sulfate binding sites by uterine epithelial cells. J Cell Physiol143:60–67.
33.
Wysocki GP, Gretzinger HA, Laupacis A, Ulan RA, Stiller CR -1983-. Fibrous hyperplasia of the gingival: side effect of cyclosporine A therapy. Oral Surg55:274–278.
34.
Yamalik N, Kiline K, Caglayan F, Eratalay K, Caglayan G -1998-. Molecular size distribution analysis of human gingival proteoglycans and glycosaminoglycans in specific periodontal diseases. J Clin Periodontol25:145–152.
